Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/bloodadvances.2020002431 http://scihub22266oqcxt.onion/10.1182/bloodadvances.2020002431 32886750!7479963!32886750     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32886750&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Blood+Adv 2020 ; 4 (17): 4147-4150 Nephropedia Template TP {{tp|p=32886750|t=2020. Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic |pdf=|usr=}}{{32886750}} gab.com Text Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic JO: Blood Adv http://www.kidney.de/pget.php?&tw=1&pmid=32886750 #FOAvip Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD34+ cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD34+ cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, white cell count (WCC) during storage, and complex product manipulation before cryopreservation were independently associated with inferior postthaw CD34+ cell recovery. Longer precryopreservation transit time and WCC were also associated with inferior postthaw CD34+ cell viability. We conclude that although postthaw CD34+ cell recovery and viability of cryopreserved allogeneic HPC is generally acceptable, there is a significant risk of poor postthaw product quality, associated with prolonged storage time, higher WCC, and complex product manipulation precryopreservation. Awareness of expected postthaw recovery and practices that influence it will assist collection, processing, and transplant centers in optimizing outcomes for transplant recipients. Twit Text FOAVip Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic ????Blood Adv http://www.kidney.de/pget.php?&tw=1&pmid=32886750 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32886750 #FOAvip English Wikipedia <ref>{{Cite pmid|32886750}}</ref> Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic #MMPMID32886750 Purtill D; Antonenas V; Chiappini P; Tong D; O'Flaherty E; Bajel A; Kabani K; Larsen S; Tan S; Hutchins C; Curtis DJ; Kennedy GA; Watson AM; Bai L; Greenwood M; Gottlieb DJ; Hamad N Blood Adv 2020[Sep]; 4 (17): 4147-4150 PMID32886750show ga Donor registries and transplantation societies recommend cryopreservation of unrelated donor hemopoietic progenitor cell (HPC) products before the recipient commences conditioning therapy to mitigate the donor and travel risks associated with the COVID-19 pandemic. However, little is known regarding the postthaw quality of such allogeneic products or the effect of precryopreservation storage and processing on these characteristics. We investigated the postthaw CD34+ cell recovery and viability of 305 allogeneic HPC products cryopreserved at 9 laboratories across Australia. Median postthaw CD34+ cell recovery was 76% and ranged from 6% to 122%. Longer transit time before cryopreservation, white cell count (WCC) during storage, and complex product manipulation before cryopreservation were independently associated with inferior postthaw CD34+ cell recovery. Longer precryopreservation transit time and WCC were also associated with inferior postthaw CD34+ cell viability. We conclude that although postthaw CD34+ cell recovery and viability of cryopreserved allogeneic HPC is generally acceptable, there is a significant risk of poor postthaw product quality, associated with prolonged storage time, higher WCC, and complex product manipulation precryopreservation. Awareness of expected postthaw recovery and practices that influence it will assist collection, processing, and transplant centers in optimizing outcomes for transplant recipients. |*Cryopreservation[MESH] |Antigens, CD34/*analysis[MESH] |COVID-19[MESH] |Cell Survival[MESH] |Coronavirus Infections/epidemiology[MESH] |Hematopoietic Stem Cell Transplantation[MESH] |Hematopoietic Stem Cells/*cytology[MESH] |Humans[MESH] |Pandemics[MESH] |Pneumonia, Viral/epidemiology[MESH]Variable CD34+ recovery of cryopreserved allogeneic HPC products: tran(epmc).pdf DeepDyve Pubget Overpricing